Clinical efficacy and safety of butylphthalide soft capsules in the treatment of Parkinson disease:a Meta-analysis
10.19845/j.cnki.zfysjjbzz.2023.0074
- VernacularTitle:丁苯酞软胶囊治疗帕金森病临床疗效和安全性的Meta分析
- Author:
Jiamin KOU
1
;
Hao GUO
1
Author Information
1. Inner Mongolia Autonomous Region People Hospital,Department of Pharmacy,Inner Mongolia Autonomous,Hohhot 010017,China
- Publication Type:Journal Article
- Keywords:
Butylphthalide;
Parkinson disease;
Clinical efficacy;
Safety;
Meta-analysis
- From:
Journal of Apoplexy and Nervous Diseases
2023;40(4):297-303
- CountryChina
- Language:Chinese
-
Abstract:
Objective To further update the evidence-based medicine evidence of clinical efficacy and safety of butylphthalide soft capsules in the treatment of Parkinson disease(PD). Methods Randomized controlled trials(RCT) on Butylphthalide soft capsules for PD was collected from PubMed,Embase,Cochrane Library,CNKI,Wanfang and CBM,the retrieval time was from inception to August 2021.The literature selection,data collection were conducted. Meta-analysis was performed by RevMan 5.3 software. Results A total of 28 studies were included and 2463 patients were included. Compared with control group,butylphthalide soft capsules could reduce UPDRS score (MD=-9.52,95%CI -11.23~-7.82,P<0.05),increase MMSE score (MD=3.40,95%CI 2.74~4.06,P<0.05) and MoCA score (MD=3.31,95%CI 3.04~3.57,P<0.05). It also could reduce CRP levels (MD=-2.37,95%CI -2.49~-2.24,P<0.05) and PARK-7 level (MD=-9.39,95%Cl -10.56~-8.22,P<0.05),increase NT-3 levels (MD=8.04,95%CI 7.01~9.07,P<0.05). However,there was no statistical difference in the number of adverse events between the treatment and control groups (RR=1.21,95%CI 0.75~1.94,P=0.43). Conclusion Butylphthalide soft capsules can improve cognitive dysfunction and other complications in Parkinson's patients,by reducing PARK-7,CRP levels and increase NT-3 levels,No serious adverse events have been observed.
- Full text:202406171050305676Clinical efficacy and safety of butylphthalide soft capsules in the treatment of Parkinson disease_a Meta-analysis.pdf
